Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Roche Immuno-Oncology, It’s Steady As She Goes

Executive Summary

Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy - as illustrated in the Pink Sheet's animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq.

Advertisement

Related Content

Roche's Oncology Strategy: The Long Game Comes Into Focus

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel